Federal Register / Vol. 82, No. 169 / Friday, September 1, 2017 / Notices 41627 

product for which FDA has regulatory 

responsibility. 

In the Federal Register of April 1, 

2015 (80 FR 17439), FDA announced the 

availability of the draft guidance. 

Interested persons were invited to 

comment by June 1, 2015. FDA revised 

the guidance as appropriate in response 

to the comments. This guidance is 

intended to provide information for 

industry and for CDRH staff on the 

processes associated with a panel 

meeting held for any of the reasons 

identified in the guidance. This 

guidance replaces the ‘‘Guidance on 

Amended Procedures for Advisory 

Panel Meetings’’ (Ref. 2) and the 

guidance document entitled ‘‘Panel 

Review of Premarket Approval 

Applications #P91–2 blue book memo’’ 

(Ref. 3). This guidance supplements 

existing FDA Agency-wide guidance on 

the conduct of Advisory Committee 

meetings. 

II. Significance of Guidance 

This guidance is being issued 

consistent with FDA’s good guidance 

practices regulation (21 CFR 10.115). 

The guidance represents the current 

thinking of FDA on the panel meeting 

process for medical devices. It does not 

establish any rights for any person and 

is not binding on FDA or the public. 

You can use an alternative approach if 

it satisfies the requirements of the 

applicable statutes and regulations. This 

guidance is not subject to Executive 

Order 12866. 

III. Electronic Access 

Persons interested in obtaining a copy 

of the guidance may do so by 

downloading an electronic copy from 

the internet. A search capability for all 

Center for Devices and Radiological 

Health guidance documents is available 

at https://www.fda.gov/MedicalDevices/ 

DeviceRegulationandGuidance/ 

GuidanceDocuments/default.htm. 

Guidance documents are also available 

at https://www.regulations.gov. Persons 

unable to download an electronic copy 

of ‘‘Procedures for Meetings of the 

Medical Devices Advisory Committee’’ 

may send an email request to CDRHGuidance@fda.hhs.gov to receive an 

electronic copy of the document. Please 

use the document number 413 to 

identify the guidance you are 

requesting. 

IV. Paperwork Reduction Act of 1995 

This guidance refers to previously 

approved collections of information 

found in FDA regulations. These 

collections of information are subject to 

review by the Office of Management and 

Budget (OMB) under the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501– 

3520). The collections of information in 

21 CFR part 807, subpart E have been 

approved under OMB control number 

0910–0120; the collections of 

information in 21 CFR part 860 have 

been approved under OMB control 

number 0910–0138; the collections of 

information in 21 CFR part 814 have 

been approved under OMB control 

number 0910–0231; and the collections 

of information in 21 CFR part 814, 

subpart H have been approved under 

OMB control number 0910–0332. 

V. References 

The following references are on 

display in the Dockets Management 

Staff (see ADDRESSES), and may be seen 

by interested persons between 9 a.m. 

and 4 p.m., Monday through Friday; 

they are also available electronically at 

https://www.regulations.gov. FDA has 

verified the Web site addresses, as of the 

date this document publishes in the 

Federal Register, but Web sites are 

subject to change over time. 

1. CDRH’s Medical Devices Advisory 

Committee, available at https:// 

www.fda.gov/AdvisoryCommittees/ 

CommitteesMeetingMaterials/Medical

Devices/MedicalDevicesAdvisoryCommittee/ 

default.htm. 

2. ‘‘Guidance for Industry and FDA Staff: 

Guidance on Amended Procedures for 

Advisory Panel Meetings,’’ July 2000, 

available at https://www.fda.gov/downloads/ 

MedicalDevices/DeviceRegulationand

Guidance/GuidanceDocuments/ 

ucm073726.pdf. 

3. ‘‘Panel Review of Premarket Approval 

Applications #P91–2 (blue book memo),’’ 

May 1991, available at https://www.fda.gov/ 

MedicalDevices/DeviceRegulationand

Guidance/GuidanceDocuments/ 

ucm081363.htm. 

Dated: August 28, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–18549 Filed 8–31–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program; List of Petitions Received 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HRSA is publishing this 

notice of petitions received under the 

National Vaccine Injury Compensation 

Program (the program), as required by 

the Public Health Service (PHS) Act, as 

amended. While the Secretary of HHS is 

named as the respondent in all 

proceedings brought by the filing of 

petitions for compensation under the 

Program, the United States Court of 

Federal Claims is charged by statute 

with responsibility for considering and 

acting upon the petitions. 

FOR FURTHER INFORMATION CONTACT: For 

information about requirements for 

filing petitions, and the program in 

general, contact Lisa L. Reyes, Acting 

Clerk, United States Court of Federal 

Claims, 717 Madison Place NW., 

Washington, DC 20005, (202) 357–6400. 

For information on HRSA’s role in the 

program, contact the Director, National 

Vaccine Injury Compensation Program, 

5600 Fishers Lane, Room 08N146B, 

Rockville, MD 20857; (301) 443–6593, 

or visit our Web site at: http://

www.hrsa.gov/vaccinecompensation/ 

index.html. 

SUPPLEMENTARY INFORMATION: The 

program provides a system of no-fault 

compensation for certain individuals 

who have been injured by specified 

childhood vaccines. Subtitle 2 of Title 

XXI of the PHS Act, 42 U.S.C. 300aa– 

10 et seq., provides that those seeking 

compensation are to file a petition with 

the U.S. Court of Federal Claims and to 

serve a copy of the petition on the 

Secretary of HHS, who is named as the 

respondent in each proceeding. The 

Secretary has delegated this 

responsibility under the program to 

HRSA. The Court is directed by statute 

to appoint special masters who take 

evidence, conduct hearings as 

appropriate, and make initial decisions 

as to eligibility for, and amount of, 

compensation. 

A petition may be filed with respect 

to injuries, disabilities, illnesses, 

conditions, and deaths resulting from 

vaccines described in the Vaccine Injury 

Table (the table) set forth at 42 CFR 

100.3. This Table lists for each covered 

childhood vaccine the conditions that 

may lead to compensation and, for each 

condition, the time period for 

occurrence of the first symptom or 

manifestation of onset or of significant 

aggravation after vaccine 

administration. Compensation may also 

be awarded for conditions not listed in 

the Table and for conditions that are 

manifested outside the time periods 

specified in the Table, but only if the 

petitioner shows that the condition was 

caused by one of the listed vaccines. 

Section 2112(b)(2) of the PHS Act, 42 

U.S.C. 300aa–12(b)(2), requires that 

‘‘[w]ithin 30 days after the Secretary 

receives service of any petition filed 


sradovich on DSK3GMQ082PROD with NOTICES
41628 Federal Register / Vol. 82, No. 169 / Friday, September 1, 2017 / Notices 

under section 2111 the Secretary shall 

publish notice of such petition in the 

Federal Register.’’ Set forth below is a 

list of petitions received by HRSA on 

July 1, 2017, through July 31, 2017. This 

list provides the name of petitioner, city 

and state of vaccination (if unknown 

then city and state of person or attorney 

filing claim), and case number. In cases 

where the Court has redacted the name 

of a petitioner and/or the case number, 

the list reflects such redaction. 

Section 2112(b)(2) also provides that 

the special master ‘‘shall afford all 

interested persons an opportunity to 

submit relevant, written information’’ 

relating to the following: 

1. The existence of evidence ‘‘that 

there is not a preponderance of the 

evidence that the illness, disability, 

injury, condition, or death described in 

the petition is due to factors unrelated 

to the administration of the vaccine 

described in the petition,’’ and 

2. Any allegation in a petition that the 

petitioner either: 

a. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition not set forth in the 

Vaccine Injury Table but which was 

caused by’’ one of the vaccines referred 

to in the Table, or 

b. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition set forth in the 

Vaccine Injury Table the first symptom 

or manifestation of the onset or 

significant aggravation of which did not 

occur within the time period set forth in 

the Table but which was caused by a 

vaccine’’ referred to in the Table. 

In accordance with Section 

2112(b)(2), all interested persons may 

submit written information relevant to 

the issues described above in the case of 

the petitions listed below. Any person 

choosing to do so should file an original 

and three (3) copies of the information 

with the Clerk of the U.S. Court of 

Federal Claims at the address listed 

above (under the heading FOR FURTHER

INFORMATION CONTACT), with a copy to 

HRSA addressed to Director, Division of 

Injury Compensation Programs, 

Healthcare Systems Bureau, 5600 

Fishers Lane, 08N146B, Rockville, MD 

20857. The Court’s caption (Petitioner’s 

Name v. Secretary of HHS) and the 

docket number assigned to the petition 

should be used as the caption for the 

written submission. Chapter 35 of title 

44, United States Code, related to 

paperwork reduction, does not apply to 

information required for purposes of 

carrying out the program. 

Dated: August 28, 2017. 

George Sigounas, 

Administrator. 

List of Petitions Filed 

1. Houston Byrd, Jr., Heath, Ohio, Court of 

Federal Claims No: 17–0900V 

2. Jacquelyn M. Will, Milwaukee, Wisconsin, 

Court of Federal Claims No: 17–0904V 

3. Christine Midnight, Albuquerque, New 

Mexico, Court of Federal Claims No: 17– 

0905V 

4. Beth Nemechek, Greeley, Colorado, Court 

of Federal Claims No: 17–0907V 

5. Patricia Woolf, Cheyenne, Wyoming, Court 

of Federal Claims No: 17–0908V 

6. Marie Schmidt, Naperville, Illinois, Court 

of Federal Claims No: 17–0913V 

7. Richard K. Parker, Richmond, Virginia, 

Court of Federal Claims No: 17–0917V 

8. Ronald Skrajner, Aurora, Ohio, Court of 

Federal Claims No: 17–0918V 

9. Anita Javorski, Mankato, Minnesota, Court 

of Federal Claims No: 17–0919V 

10. Jose Solis Marin, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0920V 

11. Lavell Maize, Boston, Massachusetts, 

Court of Federal Claims No: 17–0921V 

12. Ronald Patrick, Stuart, Florida, Court of 

Federal Claims No: 17–0922V 

13. Amy Mehl, Memphis, Tennessee, Court 

of Federal Claims No: 17–0923V 

14. Jennifer Stracick on behalf of H.S., St. 

Petersburg, Florida, Court of Federal 

Claims No: 17–0924V 

15. Rebecca Curl, Winder, Georgia, Court of 

Federal Claims No: 17–0925V 

16. Martin McGrail and Amy McGrail on 

behalf of S.M., Neptune, New Jersey, 

Court of Federal Claims No: 17–0926V 

17. Elizabeth Evans, New York, New York, 

Court of Federal Claims No: 17–0929V 

18. Arthur M. Flowers, III, West Columbia, 

South Carolina, Court of Federal Claims 

No: 17–0930V 

19. Donna Ducey, Colleyville, Texas, Court of 

Federal Claims No: 17–0933V 

20. Mary Orloski, Lewiston, Maine, Court of 

Federal Claims No: 17–0936V 

21. Yvonne Simpson, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0944V 

22. Leslie Questel on behalf of J.M., Big Bear, 

California, Court of Federal Claims No: 

17–0946V 

23. Erwin Casazza, Springfield, New Jersey, 

Court of Federal Claims No: 17–0947V 

24. Tracie Johanek, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0948V 

25. Kimberly Holway, Seattle, Washington, 

Court of Federal Claims No: 17–0949V 

26. Livania Zavala, M.D. and Nelson J. 

Spinetti, M.D. on behalf of A.S., 

Edinburg, Texas, Court of Federal Claims 

No: 17–0951V 

27. Fred A. Stover, Spring Mills, 

Pennsylvania, Court of Federal Claims 

No: 17–0952V 

28. Justin M. Gillespie, Waupun, Wisconsin, 

Court of Federal Claims No: 17–0953V 

29. Kevin McGuinness, Dade City, Florida, 

Court of Federal Claims No: 17–0954V 

30. Kathleen Peddycord Wilson, Raleigh, 

North Carolina, Court of Federal Claims 

No: 17–0955V 

31. Jamie Gardner, Camp Hill, Pennsylvania, 

Court of Federal Claims No: 17–0959V 

32. Sharifah Wilson, Philadelphia, 

Pennsylvania, Court of Federal Claims 

No: 17–0960V 

33. William Brown, Vienna, Virginia, Court 

of Federal Claims No: 17–0961V 

34. Karen Adams, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0963V 

35. Stephen E. Antisdel, Buchanan, 

Michigan, Court of Federal Claims No: 

17–0964V 

36. Jennifer Gregorino, Chattanooga, 

Tennessee, Court of Federal Claims No: 

17–0965V 

37. Rowena Adcox, Bowling Green, 

Kentucky, Court of Federal Claims No: 

17–0966V 

38. Lisa Workman, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0967V 

39. Mary Jane De La Pena, Sacramento, 

California, Court of Federal Claims No: 

17–0971V 

40. Mary Duncan, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0972V 

41. Cindy Gilliam, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0974V 

42. Jeffrey Braden, St. Louis, Missouri, Court 

of Federal Claims No: 17–0975V 

43. Janice Condara, Sugar Land, Texas, Court 

of Federal Claims No: 17–0977V 

44. George Kennedy, Austin, Texas, Court of 

Federal Claims No: 17–0978V 

45. Daphne Lattimer, Groveport, Ohio, Court 

of Federal Claims No: 17–0980V 

46. Linda Harris, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0981V 

47. Kent Kemmerer, Willoughby, Ohio, Court 

of Federal Claims No: 17–0982V 

48. Casey Humphreys on behalf of E.H., 

Jasper, Arkansas, Court of Federal Claims 

No: 17–0983V 

49. Deborah Langer, Dallas, Texas, Court of 

Federal Claims No: 17–0984V 

50. Allison Menard, Baton Rouge, Louisiana, 

Court of Federal Claims No: 17–0985V 

51. William Nischbach, Washington, District 

of Columbia, Court of Federal Claims No: 

17–0986V 

52. Tzipora Lefkowitz on behalf of M.L., New 

Square, New York, Court of Federal 

Claims No: 17–0987V 

53. Sara Torres-Ruiz, Palmdale, California, 

Court of Federal Claims No: 17–0988V 

54. Jason Quirino, Boston, Massachusetts, 

Court of Federal Claims No: 17–0989V 

55. Barbara Stoliker, Ventura, California, 

Court of Federal Claims No: 17–0990V 

56. Natalie Ben-Shoshan, Dallas, Texas, Court 

of Federal Claims No: 17–0991V 

57. Patricia Pendergrass, Washington, District 

of Columbia, Court of Federal Claims No: 

17–0992V 

58. Jamie Miller, Baltimore, Maryland, Court 

of Federal Claims No: 17–0993V 

59. Regina Stenberg, Washington, District of 

Columbia, Court of Federal Claims No: 

17–0994V 

60. Cheri Lang, Washington, District of 

Columbia, Court of Federal Claims No: 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 169 / Friday, September 1, 2017 / Notices 41629 

17–0995V 

61. Cheryl Conkle, Boston, Massachusetts, 

Court of Federal Claims No: 17–1001V 

62. Angela Dieter, Mount Joy, Pennsylvania, 

Court of Federal Claims No: 17–1002V 

63. Romana Estes, Boston, Massachusetts, 

Court of Federal Claims No: 17–1003V 

64. Anne Knudson, Phillips, Wisconsin, 

Court of Federal Claims No: 17–1004V 

65. Miguel Leal, Jr., Wyoming, Michigan, 

Court of Federal Claims No: 17–1008V 

66. Kimberly Settle, Thomasville, North 

Carolina, Court of Federal Claims No: 

17–1009V 

67. Sapna Kadakia, Washington, District of 

Columbia, Court of Federal Claims No: 

17–1011V 

68. Ricky Buras, Hattiesburg, Mississippi, 

Court of Federal Claims No: 17–1012V 

69. Ellisa Morine, Chicago, Illinois, Court of 

Federal Claims No: 17–1013V 

70. Margaret Rogers, Dresher, Pennsylvania, 

Court of Federal Claims No: 17–1014V 

71. Michael Anderson, Dresher, 

Pennsylvania, Court of Federal Claims 

No: 17–1017V 

72. Robert Wechsler, Dresher, Pennsylvania, 

Court of Federal Claims No: 17–1018V 

73. Geraldine Petrocelli, Monroe, New York, 

Court of Federal Claims No: 17–1019V 

74. Kevin McKenna, Rochester Hills, 

Michigan, Court of Federal Claims No: 

17–1021V 

75. Albert Parsons, Wartburg, Tennessee, 

Court of Federal Claims No: 17–1022V 

76. Cynthia Hackney, San Antonio, Texas, 

Court of Federal Claims No: 17–1027V 

77. Barbara Sakovits, Dresher, Pennsylvania, 

Court of Federal Claims No: 17–1028V 

78. Sheryl Attig, Greenville, South Carolina, 

Court of Federal Claims No: 17–1029V 

79. Patricia Anton, Dresher, Pennsylvania, 

Court of Federal Claims No: 17–1031V 

80. Tasha Lee and Jose Botello on behalf of 

A.B., Beverly Hills, California, Court of 

Federal Claims No: 17–1032V 

[FR Doc. 2017–18567 Filed 8–31–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center For Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 14– 

166: Early Phase Clinical Trials in Imaging 

and Image-Guided Interventions. 

Date: September 25, 2017. 

Time: 4:00 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Songtao Liu, MD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

Bethesda, MD 20817, 301–435–3578, 

songtao.liu@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 29, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–18612 Filed 8–31–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; R13 Conference 

Grant Applications. 

Date: September 21, 2017. 

Time: 11:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Jian Yang, Ph.D., Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

7111, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7799, yangj@

extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Time-Sensitive 

Obesity PAR Review. 

Date: September 29, 2017. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Michele L. Barnard, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7353, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, (301) 594–8898, 

barnardm@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; DDK–D Member 

Conflict SEP. 

Date: October 6, 2017. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Xiaodu Guo, MD, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7023, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Fellowships in 

Digestive Diseases and Nutrition. 

Date: October 12–13, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Jian Yang, Ph.D., Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

7111, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7799, yangj@

extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Fellowships in 

Diabetes, Endocrinology and Metabolic 

Diseases. 

Date: October 17, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda 

(Formerly Holiday Inn Select), 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Thomas A. Tatham, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7021, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–3993, 

tathamt@mail.nih.gov. 


sradovich on DSK3GMQ082PROD with NOTICES